USANA Health Sciences Director Acquires 1,632 Shares Through Restricted Stock Unit Vesting

Director's Equity Acquisition Through Restricted Stock Unit Vesting

Frederic J. Winssinger, who serves as a director of USANA Health Sciences Inc., executed a transaction on July 23, 2026, involving the acquisition of 1,632 shares of the company's common stock. The disclosure indicates this acquisition resulted from the vesting of restricted stock units, a form of equity compensation commonly granted to board members and senior executives. The transaction was reported in a regulatory filing submitted to the Securities and Exchange Commission on July 27, 2026.

According to the disclosure, Winssinger holds the shares in direct beneficial ownership. The filing shows that following this transaction, Winssinger's total direct beneficial ownership of USANA common stock stands at 9,733 shares. The restricted stock units that vested on the transaction date represent contingent rights to receive one share of USANA common stock for each unit, as explained in the filing's response section.

Vesting Schedule and Future Equity Compensation Releases

The restricted stock units underlying this transaction are scheduled to vest in four equal quarterly installments over a period of approximately one year. The filing specifies vesting dates of July 23, 2026 (the initial 25 percent tranche), followed by October 22, 2026, January 21, 2027, and April 22, 2027, with each date representing the release of an additional 25 percent of the units. This staggered vesting schedule is a standard practice in equity compensation design, intended to align the interests of board members and executives with long-term company performance and shareholder value.

The total number of restricted stock units involved in this arrangement is 1,632 shares, with the first quarter of units having vested on the transaction date itself. This means Winssinger will receive an additional 408 shares (approximately 25 percent of the total grant) on each of the three remaining vesting dates, assuming the units continue to vest as scheduled. The disclosure does not indicate any conditions that would prevent the scheduled vesting of the remaining units.

Winssinger's Board Role and Beneficial Ownership Position

The filing identifies Frederic J. Winssinger as a director of USANA Health Sciences Inc., based on his checked status in the "Director" box on the regulatory form. Directors typically receive equity-based compensation as part of their board service arrangements, reflecting market practice for publicly traded companies seeking to align director interests with those of shareholders. The disclosure provides Winssinger's address as located in Phoenix, Arizona, though the filing does not elaborate on his specific board committees or responsibilities.

Following the July 23, 2026 vesting event, Winssinger's disclosed direct beneficial ownership of USANA common stock is 9,733 shares. The filing indicates this ownership is held directly, rather than indirectly through any trust, entity, or arrangement. The immediate share price impact was not clear from available public information. Investors monitoring insider transactions may track whether additional share acquisitions or dispositions occur as the remaining restricted stock units vest over the coming months.

Restricted Stock Units as Equity Compensation Mechanism

Restricted stock units, or RSUs, are a widely used form of equity compensation in the public company sector. Unlike stock options, which require the holder to exercise and pay a purchase price to acquire shares, RSUs vest and automatically convert into shares of common stock on specified dates, provided the holder remains employed or continues to serve in their role. In this case, the RSU grant to Winssinger has been structured with quarterly vesting tranches, which is a common approach to distribute the value and tax consequences of equity compensation over time.

The filing notes that each restricted stock unit represents a contingent right to receive one share of USANA common stock. This means that as each vesting date arrives, the contingent right becomes a vested right, and one share of actual common stock is issued to Winssinger's account. The zero dollar price notation in the filing's derivative securities table reflects that RSUs do not have an exercise price in the traditional sense—they vest and convert into shares without requiring any cash outlay from the recipient. This differs fundamentally from stock options, which would require the holder to pay an exercise price to acquire the underlying shares.

Filing Submission and Regulatory Compliance

The disclosure was filed on July 27, 2026, four days after the transaction date of July 23, 2026. The form indicates that Joshua Foukas, acting as attorney-in-fact for Winssinger, signed the filing on behalf of the reporting person. This delegated signing arrangement is permitted under SEC regulations when a reporting person authorizes an attorney or other agent to execute regulatory filings on their behalf. The filing was submitted as a single reporting person form, rather than a joint or group filing, indicating that Winssinger is the sole reporting person for this transaction.

The regulatory framework governing this disclosure is Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and 10 percent beneficial owners of public companies to report changes in their ownership of company securities. The SEC provides a standardized form for these disclosures to ensure consistent and transparent reporting of insider transactions across all public markets. Investors and market participants use these filings to monitor the investment activity of company insiders, which can provide insights into their confidence in the company's prospects and valuation.

Market Context and Investor Considerations

USANA Health Sciences Inc. is a multinational network marketing company that manufactures and sells nutritional products, weight management solutions, and personal care items. The company operates through a network of independent distributors in markets across North America, Europe, Asia, and other regions. As a director, Winssinger's equity compensation through restricted stock units reflects the company's approach to compensating board members with a combination of cash and equity-based pay structures.

Investors monitoring insider transactions at USANA may view equity vesting by board members as part of the normal course of compensation administration, distinct from open market purchases or dispositions that might signal director sentiment regarding company valuation. The quarterly vesting schedule means that Winssinger's shareholdings will incrementally increase over the next several months as each tranche vests, assuming no intervening changes to his directorship status. The disclosure provides transparency into these equity compensation arrangements, allowing shareholders to understand the composition and timing of insider equity ownership.

No Material Adverse Changes or Contingencies Indicated

The filing contains no indications of material adverse changes, contingencies, or unusual circumstances affecting the restricted stock unit grant or vesting schedule. The disclosure is structured as a routine equity compensation transaction with a standard vesting schedule. The filing provides no commentary on market conditions, company performance, or any factors that might affect the completion of the vesting schedule or Winssinger's continued service as a director.

The form does not include any statements regarding Winssinger's views on the company's valuation, future prospects, or the sufficiency of the compensation provided through the restricted stock unit grant. As with all insider transaction filings, investors should interpret this disclosure as a factual report of ownership changes rather than as an endorsement or criticism of current market prices. The transaction itself—the vesting of equity compensation—represents a pre-determined event rather than a voluntary market trade that might indicate Winssinger's assessment of share valuation.

Comparison to Prior USANA Insider Activity Patterns

While the filing does not provide historical context or comparative data regarding prior insider transactions at USANA Health Sciences, the vesting of restricted stock units is a regularly occurring transaction at publicly traded companies. The filing indicates that Winssinger had previously accumulated restricted stock units, and this filing documents one quarterly vesting tranche from that grant. Investors seeking to understand patterns of insider compensation or trading activity at USANA would need to review multiple filings filed over time to identify trends in equity awards, vesting schedules, or subsequent open market transactions by directors and officers.

The structure of this restricted stock unit grant—with equal quarterly vesting over one year—is consistent with standard market practice for director compensation and does not appear to deviate from typical patterns. The filing does not indicate whether this is Winssinger's first equity grant from USANA or one of multiple tranches. Investors interested in comprehensive information regarding insider compensation policies, board pay structures, and historical vesting patterns would typically consult the company's proxy statement or other governance disclosures that address these topics in greater detail than individual insider transaction filings.